Taken together, our results indicated that CRL4 and BIRC3 upregulation in ovarian cancer cells led to chemoresistance to cisplatin, suggesting that CRL4 and BIRC3 might serve as novel targets for relapsed patients after treatment with cisplatin and its derivatives. Here, IL17RB is linked to ovarian cancer.